Trial Profile
A multicenter phase II study evaluating denosumab (XGEVA) in combination with nivolumab (OPDIVO) as second-line therapy for patients with stage IV non-small–cell lung cancer (squamous and non-squamous) with bone metastases
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Bone metastases; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms DENIVOS
- 25 Oct 2023 This trial has been completed in France(End Date: 19 Oct 2023), according to European Clinical Trials Database record.
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress
- 19 Jul 2022 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.